Clinical Trials Logo
  1. Home
  2. Renal Transplant Rejection
  3. NCT00771745

Prospective Pilot Study of Pre-Transplant Thymoglobulin Administration in Living Donor Renal Transplant Recipients

Renal Transplant Rejection Clinical Trial

Official title:
Prospective, Single Center, Pilot Study of Pretransplant Thymoglobulin Administration and Early Corticosteroid Withdrawal in Living Donor Renal Transplant Recipients Under Mycophenolate Mofetil (MMF) and Tacrolimus Immunosuppression

Clinical Trial Summary

To determine how safe and effective giving Thymoglobulin before transplantation to patients who are going to be receiving kidney transplants.

Clinical Trial Description

We will evaluate the therapeutic efficacy of administering Thymoglobulin® induction pre-transplantation in renal allograft recipients. Patients receiving pre-transplant Thymoglobulin will be evaluated for acute rejection (Banff '97 criteria), survival, and safety at 6 months. Overall the use of Thymoglobulin induction pre-transplantation will be safe and effective. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00771745
Study type Interventional
Source University of Cincinnati
Contact
Status Completed
Phase Phase 4
Start date September 2008
Completion date July 2010
View Details
See also
  Status Clinical Trial Phase
Completed NCT03140514 - Urine CXCL10 Chemokine Monitoring Post-renal Transplant N/A
Completed NCT02581436 - Testing Immunosuppression Threshold in Renal Allografts To Extend eGFR N/A
Active, not recruiting NCT02409940 - To Elucidate the Effect of Mesenchymal Stem Cells on the T Cell Repertoire of the Kidney Transplant Patients Phase 1
Completed NCT02377193 - Simulect Versus ATG in Sensitized Renal Transplant Patient Phase 4
Not yet recruiting NCT05385432 - Induction in Sensitized Kidney Transplant Recipients Without Pre-existing Donor-specific antiboDies Phase 3
Completed NCT01953120 - Mechanisms of Belatacept Effect on Alloimmunity and Antiviral Response After Kidney Transplantation (BMS IM 103-309) Phase 4
Terminated NCT01324934 - Efficacy and Safety of ATG-Fresenius Following a Renal Transplantation, Without Corticosteroids Phase 3
Terminated NCT00983645 - A Trial Comparing Prograf and Neoral Use in Kidney Transplant Recipients of Hispanic Ethnicity Phase 4
Active, not recruiting NCT04530630 - Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide After Renal Transplant Phase 4
Recruiting NCT03707262 - Study of Combined Kidney and Blood Stem Cell Transplant From a Brother or Sister Donor Phase 1/Phase 2
Completed NCT02006108 - Imaging Kidney Transplant Rejection Using Ferumoxytol-Enhanced Magnetic Resonance N/A
Recruiting NCT03991780 - Fostamatinib in the Treatment of Chronic Active Antibody Mediated Rejection Phase 1/Phase 2
Completed NCT02733029 - Contrast Enhanced Ultrasonography to Detect Human Renal Transplant Rejection Phase 2
Active, not recruiting NCT02057965 - Mesenchymal Stromal Cell Therapy in Renal Recipients Phase 2
Completed NCT00658073 - Induction Therapy With Autologous Mesenchymal Stem Cells for Kidney Allografts N/A
Terminated NCT03646344 - Heme Arginate in Transplantation Study Phase 3
Completed NCT02866682 - Prospective Study Comparing Brand and Generic Immunosuppression on Transplant Outcomes, Adherence, & Immune Response in Kidney Transplant Recipients Phase 4
Not yet recruiting NCT06438107 - Deep Phenotyping of the Renal Allograft to Prognosticate Clinical Outcomes
Completed NCT02500251 - Belimumab Impacting Transplant Eligibility Phase 1/Phase 2
Completed NCT00866879 - Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients Phase 4